Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus - Institut Pasteur Access content directly
Journal Articles Gut Year : 2018

Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus

Gino Miele
  • Function : Correspondent author
  • PersonId : 1031303

Connectez-vous pour contacter l'auteur

Abstract

Objective Recently approved direct acting antivirals provide transformative therapies for chronic hepatitis C virus (HCV) infection. The major clinical challenge remains to identify the undiagnosed patients worldwide, many of whom live in low-income and middle-income countries, where access to nucleic acid testing remains limited. The aim of this study was to develop and validate a point-of-care (PoC) assay for the qualitative detection of HCV RNA. Design We developed a PoC assay for the qualitative detection of HCV RNA on the PCR Genedrive instrument. We validated the Genedrive HCV assay through a case–control study comparing results with those obtained with the Abbott RealTime HCV test. Results The PoC assay identified all major HCV genotypes, with a limit of detection of 2362 IU/mL (95% CI 1966 to 2788). Using 422 patients chronically infected with HCV and 503 controls negative for anti-HCV and HCV RNA, the Genedrive HCV assay showed 98.6% sensitivity (95% CI 96.9% to 99.5%) and 100% specificity (95% CI 99.3% to 100%) to detect HCV. In addition, melting peak ratiometric analysis demonstrated proof-of-principle for semiquantification of HCV. The test was further validated in a real clinical setting in a resource-limited country. Conclusion We report a rapid, simple, portable and accurate PoC molecular test for HCV, with sensitivity and specificity that fulfils the recent FIND/WHO Target Product Profile for HCV decentralised testing in low-income and middle-income countries. This Genedrive HCV assay may positively impact the continuum of HCV care from screening to cure by supporting real-time treatment decisions.

Domains

Immunology
Fichier principal
Vignette du fichier
gutjnl-2017-315783.full.pdf (605.17 Ko) Télécharger le fichier
Origin Publication funded by an institution
Loading...

Dates and versions

pasteur-01769953 , version 1 (18-04-2018)

Licence

Identifiers

Cite

Alba Llibre, Yusuke Shimakawa, Estelle Mottez, Shaun Ainsworth, Tan-Phuc Buivan, et al.. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut, 2018, 11, pp.1-8. ⟨10.1136/gutjnl-2017-315783⟩. ⟨pasteur-01769953⟩
406 View
127 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More